全文获取类型
收费全文 | 2686篇 |
免费 | 360篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 65篇 |
儿科学 | 146篇 |
妇产科学 | 293篇 |
基础医学 | 215篇 |
口腔科学 | 36篇 |
临床医学 | 946篇 |
内科学 | 339篇 |
皮肤病学 | 65篇 |
神经病学 | 127篇 |
特种医学 | 255篇 |
外科学 | 160篇 |
综合类 | 61篇 |
一般理论 | 6篇 |
预防医学 | 138篇 |
眼科学 | 11篇 |
药学 | 80篇 |
肿瘤学 | 112篇 |
出版年
2023年 | 52篇 |
2022年 | 14篇 |
2021年 | 19篇 |
2020年 | 44篇 |
2019年 | 29篇 |
2018年 | 68篇 |
2017年 | 97篇 |
2016年 | 84篇 |
2015年 | 105篇 |
2014年 | 112篇 |
2013年 | 115篇 |
2012年 | 66篇 |
2011年 | 89篇 |
2010年 | 132篇 |
2009年 | 124篇 |
2008年 | 78篇 |
2007年 | 80篇 |
2006年 | 85篇 |
2005年 | 57篇 |
2004年 | 46篇 |
2003年 | 62篇 |
2002年 | 52篇 |
2001年 | 66篇 |
2000年 | 51篇 |
1999年 | 77篇 |
1998年 | 110篇 |
1997年 | 125篇 |
1996年 | 115篇 |
1995年 | 100篇 |
1994年 | 68篇 |
1993年 | 60篇 |
1992年 | 36篇 |
1991年 | 37篇 |
1990年 | 29篇 |
1989年 | 54篇 |
1988年 | 45篇 |
1987年 | 28篇 |
1986年 | 45篇 |
1985年 | 46篇 |
1984年 | 32篇 |
1983年 | 30篇 |
1982年 | 26篇 |
1981年 | 21篇 |
1980年 | 17篇 |
1979年 | 16篇 |
1978年 | 21篇 |
1977年 | 21篇 |
1976年 | 18篇 |
1975年 | 20篇 |
1966年 | 12篇 |
排序方式: 共有3055条查询结果,搜索用时 15 毫秒
31.
32.
33.
C KAPPAGODA DN SCHELL RM HANSON & P HUTCHINS 《Journal of paediatrics and child health》1998,34(6):508-512
34.
Kinta Beaver PhD MRes BA DPSN RGN David Jones MD FRCS † Shabbir Susnerwala MD FRCR ‡ Olive Craven MSc RGN RM Onc.Cert § Mary Tomlinson BA RGN ¶ Gary Witham BA RGN Onc.Cert PG.Cert Karen A Luker PhD BNurs FMedSci †† 《Health expectations》2005,8(2):103-113
OBJECTIVES: To explore patient views on participation in treatment, physical care and psychological care decisions and factors that facilitate and hinder patients from making decisions. DESIGN: Qualitative study using semi-structured interviews with patients. SETTING AND PARTICIPANTS: Three NHS Trusts in the north-west of England. Theoretical sampling including 41 patients who had been treated for colorectal cancer. RESULTS: For patients, participation in the decision-making process was about being informed and feeling involved in the consultation process, whether patients actually made decisions or not. The perceived availability of treatment choices (surgery, radiotherapy, chemotherapy) was related to type of treatment. Factors that impacted on whether patients wanted to make decisions included a lack of information, a lack of medical knowledge and trust in medical expertise. Patients perceived that they could have a more participatory role in decisions related to physical and psychological care. CONCLUSION: This study has implications for health professionals aiming to implement policy guidelines that promote patient participation and shared partnerships. Patients in this study wanted to be well informed and involved in the consultation process but did not necessarily want to use the information they received to make decisions. The presentation of choices and preferences for participation may be context specific and it cannot be assumed that patients who do not want to make decisions about one aspect of their care and treatment do not want to make decisions about other aspects of their care and treatment. 相似文献
35.
Dan W Haupt Angela Luber Justin Maeda Angela K Melson Julie A Schweiger John W Newcomer 《Neuropsychopharmacology》2005,30(1):184-191
Alterations in plasma leptin have been reported in schizophrenia patients treated with antipsychotics, suggesting the hypothesis that impairments in leptin secretion or signaling might play a role in antipsychotic-induced weight gain. Plasma leptin was measured in 72 schizophrenia patients chronically treated with olanzapine (n=27), risperidone (n=24) or typical antipsychotics (n=21) and 124 healthy adult control subjects. ANCOVA was used to test effects of adiposity (body mass index kg/m2; BMI), subject group (treated patients vs untreated controls), and treatment group (specific medication groups and untreated controls) on plasma leptin concentrations. Additional analyses were performed in a subset of patients and controls individually matched for BMI to further assess group differences in plasma leptin independent of adiposity. BMI strongly predicted plasma leptin concentrations in the overall sample. In addition, a significant three-way interaction between BMI, subject group, and gender was observed. In the individually BMI-matched sample, modestly reduced plasma leptin levels (effect size 0.4 SD) were observed in treated patients in comparison to the BMI-matched healthy controls, with both groups including males and females. However, no differences in plasma leptin levels were observed in the matched sample when separately comparing male patients vs untreated male controls and female patients vs untreated female controls. Plasma leptin in chronically treated patients with schizophrenia is strongly predicted by adiposity, similar to untreated healthy individuals despite adequate power to detect a difference. The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications. 相似文献
36.
M Lanciotti C Dufour L Corral P Di Michele S Pigullo G De Rossi G Basso A Leszl M Luciani L Lo Nigro C Micalizzi M G Valsecchi A Biondi R Haupt 《Leukemia》2005,19(2):214-216
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a detoxification enzyme that protects cells against oxidative stress and toxic quinones. A polymorphism (C609T) in the gene produces in the heterozygous individuals (C/T) a reduction and in those homozygous for the variant allele (T/T) the abolishment of NQO1 protein activity. To assess whether NQO1 inactivating polymorphism (CT/TT) was a possible risk factor for infant acute lymphoblastic leukemia (iALL), we investigated the distribution of NQO1 genotype in 50 iALL patients, 32 with MLL gene rearrangements (MLL+) and 18 without (MLL-). As controls, 106 cases of pediatric ALL (pALL), and 147 healthy subjects were also studied. Compared to normal controls, the frequency of the low/null activity NQO1 genotypes was significantly higher in the iALL MLL- (72 vs 38%, P=0.006; odds ratio (OR) 4.22, 95% confidence interval (CI) 1.43-12.49), while no differences were observed in iALL MLL+ (44 vs 38%, P=0.553; OR 1.26, 95% CI 0.58-2.74). Similar results were observed when pALL were used as control. Our results indicate that only the iALL patients without MLL rearrangements had a significantly higher frequency of NQO1 genotypes associated with low/null activity enzyme, suggesting a possible role for NQO1 gene as an MLL-independent risk factor, in the leukemogenic process of this subtype of iALL. 相似文献
37.
Granulocyte colony-stimulating factor (G-CSF) induces rapid phosphorylation of JAK kinases as well as activation of the p21ras route through interaction with its specific receptor (G-CSF-R). The cytoplasmic membrane-proximal region of G-CSF-R (amino acids 631 to 684) is necessary for proliferation induction and activation of JAK2. In contrast, activation of Shc and Syp, signaling molecules implicated in the p21ras signaling route, depends on the phosphorylation of tyrosine residues located in the membrane-distal region (amino acids 685 to 813) of G-CSF-R. We investigated whether G-CSF-induced activation of signaling complexes of the p21ras route depends on the function of the membrane-proximal cytoplasmic region of G-CSF-R. A G- CSF-R mutant was constructed in which tryptophan 650 was replaced by arginine and expressed in BAF3 cells (BAF/W650R). In contrast to BAF3 cell transfectants expressing wild-type G-CSF-R, BAF/W650-R cells did not proliferate and did not show activation of JAK2, STAT1, or STAT3 in response to G-CSF. Immunoprecipitations with anti-Shc and anti-Grb2 antisera showed that mutant W650R also failed to activate Syp and Shc. These data indicate that the membrane-proximal cytoplasmic domain of G- CSF-R is not only crucial for proliferative signaling and activation of JAK2 and STATs, but is also required for activation of the p21ras route, which occurs via the membrane-distal region of G-CSF-R. 相似文献
38.
Dziennis S; Van Etten RA; Pahl HL; Morris DL; Rothstein TL; Blosch CM; Perlmutter RM; Tenen DG 《Blood》1995,85(2):319-329
CD11b is the alpha chain of the Mac-1 integrin and is preferentially expressed in myeloid cells (neutrophils, monocytes, and macrophages). We have previously shown that the CD11b promoter directs cell-type- specific expression in myeloid lines using transient transfection assays. To confirm that these promoter sequences contain the proper regulatory elements for correct myeloid expression of CD11b in vivo, we have used the -1.7-kb human CD11b promoter to direct reporter gene expression in transgenic mice. Stable founder lines were generated with two different reporter genes, a Thy 1.1 surface marker and the Escherichia coli lacZ (beta-galactosidase) gene. Analysis of founders generated with each reporter demonstrated that the CD11b promoter was capable of driving high levels of transgene expression in murine macrophages for the lifetime of the animals. Similar to the endogenous gene, transgene expression was preferentially found in mature monocytes, macrophages, and neutrophils and not in myeloid precursors. These experiments indicate that the -1.7 CD11b promoter contains the regulatory elements sufficient for high-level macrophage expression. This promoter should be useful for targeting heterologous gene expression to mature myeloid cells. 相似文献
39.
Harriet Chan-Myers BS RM David McAlister PhD ABMM Patricia Antonoplos PhD 《American journal of infection control》1997,25(6):471-476
Controversy exists concerning the degree of microbial contamination associated with the us of rigid lumened medical devices, the efficacy of standard cleaning techniques used to remove pathogenic microorganisms from lumen channels, and whether patients are placed at risk of cross infection because of microbial contamination. In this study the level and types of microorganisms found on rigid lumened medical devices before and after cleaning in a hospital environment were investigated. The bioburden level after clinical use was found to be relatively low, ranging from 101 to 104 colony forming units (CFU) per device. After the instruments were cleaned, none of the devices studied contained bioburden levels greater than 104 CFU and 83% had bioburden levels less than or equal to 102 CFU. The bioburden present before cleaning was comprised of organisms derived from the handling of the device, from the hospital environment, and from the patient. The bioburden present after cleaning was comprised of organisms typically derived from the handling of the device and from the hospital environment. The level of bioburden per device was also related to the anatomic site where the device was used, with lower numbers of organisms found on devices exposed to sterile body sites and the respiratory tract. 相似文献
40.
A feasibility study on using tablet personal computers for self‐reported symptom assessment in newly diagnosed lung cancer patients 下载免费PDF全文